*Department of Obstetrics and Gynecology, Stanford University Medical Center, Stanford, CA. †Departments of Clinical Pharmacy, Medicine, Epidemiology, and Biostatistics, University of California San Francisco, San Francisco, CA. ‡Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA. §Department of Pathology, University of California San Francisco, San Francisco, CA
Supported by the National Institutes of Health Women's Reproductive Health Research Grant (5 K12 HD01249), Gender Effects on HIV Biology Grant (P01 HD4053), and NIH/National Center for Research Resources University of California San Francisco Clinical and Translational Science Institute Grant Number UL1 RR024131.
Preliminary data were presented in abstract form at the National Institutes of Health Women's Reproductive Health Research Conference, June 1-3, 2008, Rochester, NY.
To the Editors:
Vaginally applied microbicides are being evaluated for efficacy in the prevention of sexual HIV transmission. These studies are based on a model in which the vagina and ectocervix are the anatomic sites of HIV transmission1; whether transmission can also occur in the upper genital tract (UGT: endocervix and endometrium) is not known. Vaginally administered gels and creams rapidly gain entrance into the UGT.2 Nonoxynol-9 (N-9) is a nonionic detergent that failed to protect against HIV transmission in clinical trials and was associated with increased acquisition of HIV in high prevalence settings.3 This latter finding was attributed to N-9-associated lower genital tract irritation and genital ulceration. Various subsequent microbicides were associated with no protection or potential increased risk of HIV acquisition, despite the apparent absence of inflammatory effects on the lower genital tract1; microbicide-induced effects on the UGT may explain these findings. We undertook a pilot study of inflammatory effects of N-9 on the UGT using paired endometrial biopsy (EMB) specimens from women in the luteal phase of the menstrual cycle before and after vaginal exposure to N-9.
The study protocol was approved by the University of California San Francisco Committee on Human Research. Inclusion criteria were as follows: age 18-40 years; HIV negative; 21-35 day menstrual cycles; and agreement to avoid use of extraneous intravaginal products for the study duration. Exclusion criteria included the following: pregnancy or attempting to conceive; abnormal Pap test within the past 12 months; recent use of intravaginal or intrauterine contraceptives; use of exogenous sex hormones; and immunocompromised status. Participants were tested for HIV, pregnancy, and sexually transmitted infections and were instructed in the use of luteinizing hormone (LH) surge predictor kits (ClearBlue Easy Ovulation Test, Inverness Medical Innovations, Delaware, DE). Subjects returned 8-10 days after the LH surge for the first (pre-N-9) EMB. Participants were then provided with intravaginal N-9 [4% N-9 contraceptive gel (Conceptrol, Ortho, Raritan, NJ)] and instructed to apply it intravaginally every night, beginning after their next menses, and continuing until their next study visit resulting in usage of approximately 2-3 weeks depending on cycle length. Participants returned 8-10 days after the next LH surge for post-N-9 EMB. Standard hematoxylin and eosin-stained slides were prepared from formalin-fixed paraffin-embedded EMB samples for endometrial dating by 2 independent board-certified pathologists; in cases where the results were discordant, a third pathologist was consulted. Immunohistochemistry was used to identify T cells (CD4, CD8), macrophages (CD68), B cells (CD20), natural killer cells (CD56), and regulatory T cells (FoxP3+) using published techniques.4,5 Image analysis software was used to measure the area of stromal regions of interest (excluding epithelium, glands, and vessels). The number of stained cells (counted visually) was divided by the area of the region of interest to determine stromal density of each cell type.
Forty-one women completed telephone screening. Twenty-seven women were invited for an initial screening and consent visit. Of those women, 19 presented for initial screening and consented to participate in the study. Two women were excluded secondary to pregnancy, and 14 presented for the first EMB visit. The cervix of 1 subject could not be dilated sufficiently for EMB, and 3 subjects did not tolerate EMB, leaving 10 subjects who underwent at least 1 biopsy. Six subjects completed all procedures. One EMB sample obtained at the second biopsy visit was classified histologically as inadequate, and 1 sample was in the proliferative rather than secretory phase at the second visit, resulting in 4 paired secretory EMB sample sets for analysis. Of these, 2 sample sets had matched midsecretory endometrium in both pre-N-9 and post-N-9 samples (N9011 and N9034), 1 set had matched early secretory endometrium (N906), and 1 was midsecretory in the pre-N-9 and early secretory in the post-N-9 sample (N9032). Results of immunohistochemical assessment (Fig. 1) demonstrated increased densities of CD8+ cells and FOXP3+ cells after N-9 exposure in all 4 paired samples. The density of CD8+ cells increased from 1.7-fold to 4.8-fold (mean 2.7). The density of FOXP3+ cells increased from 1.2-fold to 3.8-fold (mean 2.3). The densities of other cell types did not demonstrate consistent patterns of change after N-9 exposure.
Paired endometrial sampling before and after exposure to intravaginal products is a powerful research tool for assessing microbicide effects on the UGT, yet our results demonstrate the challenges of this experimental approach due to difficulties in matching the phase of the cycle for sampling and heterogeneity of cell densities within EMB samples. Despite these shortcomings, our results indicate that vaginal N9 may have inflammatory effects on the endometrium as measured by increased densities of endometrial CD8+ cells and FOXP3+ cells. Further studies into the female UGT as a portal for HIV acquisition are needed to accurately assess the safety of vaginal microbicides. To this end, improved methods for the collection of cycle-matched, paired endometrial samples will be helpful.
The authors thank Ms. Niloufar Ameli for assistance in developing data collection materials; Rebecca Packard, Portia Daniels, and Jane Pannell for recruitment of participants and data and specimen collection; Drs. Joseph Rabban and Charles Zaloudek for histological assessment of endometrial samples; and Margaret Takeda for technical support. We thank the volunteer participants for their efforts essential to this work.
Lisa Rahangdale, MD, MPH*
Ruth M. Greenblatt, MD†
Jean Perry, MSN, NP‡
Teresa M. Darragh, MD§
Akiko Kobayashi, RN, PhD‡
Karen K. Smith-McCune, MD, PhD‡
*Department of Obstetrics and Gynecology, Stanford University Medical Center, Stanford, CA
†Departments of Clinical Pharmacy, Medicine, Epidemiology, and Biostatistics, University of California San Francisco, San Francisco, CA
‡Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA
§Department of Pathology, University of California San Francisco, San Francisco, CA
1. Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis
2. Barnhart KT, Stolpen A, Pretorius ES, et al. Distribution of a spermicide containing Nonoxynol-9 in the vaginal canal and the upper female reproductive tract. Hum Reprod
3. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet
4. Kobayashi A, Greenblatt RM, Anastos K, et al. Functional attribute of mucosa immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res
5. Kobayashi A, Weinberg V, Darragh TM, et al. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol